Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC-IL-2
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Subcutaneous
01
Overview
ALVAC-IL-2 is a recombinant canarypox virus (ALVAC) vector engineered to express interleukin 2 (IL-2), used as an immunotherapy primarily in veterinary medicine. The drug acts by delivering the gene for IL-2 directly into tissues or tumors, leading to local production of this cytokine and stimulation of anti-tumor immune responses. It has been studied and approved for use in cats with fibrosarcoma as an adjuvant therapy post-surgery to delay tumor recurrence and has also shown promise in treating sarcoid tumors in horses via intratumoral injection. In human clinical trials, intratumoral administration of ALVAC-hIL-2 was evaluated for melanoma and leiomyosarcoma skin metastases. The mechanism involves local immune activation through increased T-cell activity mediated by IL-2 expression at the site of administration[1][5][6][7].
- Brand names
- Oncept IL-2
- Other names
- feline interleukin-2 immunomodulator vaccinerecombinant canarypox virus expressing IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on ALVAC-IL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC-IL-2.